Recent advances in psoriasis and eczema genetics have not only led to innovative interventions and new drug pipelines, in some cases they also allow us to distinguish which patient responds better to which biologic treatment. Prof. Jonathan Barker (Kings College London, United Kingdom) discussed the direct clinical implications that psoriasis and atopic dermatitis (AD) genetics have realised . Furthermore, the main genetic determinant for psoriasis, HLA-C*06:02, directs an autoimmune response against melanocytes through autoantigen presentation in psoriasis through ADAMTSL5, a melanocyte autoantigen .
Heritability is major factor of AD and psoriasis, as demonstrated in twin studies, where identical twins have a 25% concordance, whereas fraternal twins have only slightly higher concordance than the general population . If a cohort has large numbers of adequately phenotyped patients, genome-wide association scanning (GWAS) can be an excelle...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Granulomatous rosacea: exploratory histological markers Next Article
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.